Compare Stocks

Date Range: 

 AmgenGilead SciencesModernaBiogenBioNTech
SymbolNASDAQ:AMGNNASDAQ:GILDNASDAQ:MRNANASDAQ:BIIBNASDAQ:BNTX
Price Information
Current Price$254.21$66.54$163.15$274.04$183.71
52 Week RangeHoldBuyHoldHoldHold
MarketRank™
Overall Score2.32.81.61.70.9
Analysis Score2.24.32.22.11.2
Community Score3.03.33.03.02.7
Dividend Score2.53.30.00.00.0
Ownership Score1.71.70.81.70.0
Earnings & Valuation Score1.91.31.91.90.6
Analyst Ratings
Consensus RecommendationHoldBuyHoldHoldHold
Consensus Price Target$255.62$99.74$156.88$305.57$106.50
% Upside from Price Target0.55% upside49.89% upside-3.84% downside11.51% upside-42.03% downside
Trade Information
Market Cap$146.06 billion$83.78 billion$65.35 billion$41.26 billion$44.37 billion
Beta0.760.511.730.53-1.74
Average Volume2,723,2558,289,93412,035,3641,201,7622,495,841
Sales & Book Value
Annual Revenue$23.36 billion$22.45 billion$60.21 million$14.38 billion$121.63 million
Price / Sales6.253.731,085.302.87364.79
Cashflow$19.58 per share$7.89 per shareN/A$38.38 per shareN/A
Price / Cash12.988.43N/A7.14N/A
Book Value$16.28 per share$17.90 per share$3.49 per share$73.93 per share$2.44 per share
Price / Book15.613.7246.753.7175.29
Profitability
Net Income$7.84 billion$5.39 billion$-514,020,000.00$5.89 billion$-200,540,000.00
EPS$14.82$6.14($1.55)$33.57($0.95)
Trailing P/E Ratio20.5068.60N/A9.07N/A
Forward P/E Ratio14.959.4915.6110.9013.33
P/E Growth1.900.670.531.04N/A
Net Margins29.42%5.48%-242.73%35.63%-250.12%
Return on Equity (ROE)95.55%37.77%-28.11%51.00%-66.72%
Return on Assets (ROA)15.52%12.76%-20.31%23.54%-41.73%
Dividend
Annual Payout$7.04$2.84N/AN/AN/A
Dividend Yield2.77%4.27%N/AN/AN/A
Three-Year Dividend Growth39.13%30.77%N/AN/AN/A
Payout Ratio47.50%46.25%N/AN/AN/A
Years of Consecutive Dividend Growth1 Years1 YearsN/AN/AN/A
Debt
Debt-to-Equity Ratio3.12%1.65%0.04%0.69%N/A
Current Ratio2.28%3.25%2.43%2.06%4.07%
Quick Ratio1.88%3.15%2.43%1.79%4.02%
Ownership Information
Institutional Ownership Percentage75.23%76.36%51.21%83.51%10.75%
Insider Ownership Percentage0.36%0.13%29.20%0.54%N/A
Miscellaneous
Employees24,30013,6001,3009,1001,941
Shares Outstanding574.55 million1.26 billion400.53 million150.56 million241.52 million
Next Earnings Date7/27/2021 (Estimated)7/29/2021 (Estimated)8/4/2021 (Estimated)7/28/2021 (Estimated)5/10/2021 (Confirmed)
OptionableOptionableOptionableOptionableOptionableNot Optionable
SourceHeadline
Pfizer and BioNTech to donate vaccine doses for athletes ahead of Tokyo Olympics in July - MarketWatchPfizer and BioNTech to donate vaccine doses for athletes ahead of Tokyo Olympics in July - MarketWatch
marketwatch.com - May 7 at 7:28 PM
NC coronavirus update May 7: Pfizer and BioNTech begin application for full FDA approval of their COVID-19 vaccine - WTVD-TVNC coronavirus update May 7: Pfizer and BioNTech begin application for full FDA approval of their COVID-19 vaccine - WTVD-TV
abc11.com - May 7 at 7:28 PM
Pfizer and BioNTech begin the process of seeking full U.S. approval for their Covid vaccine - CNBCPfizer and BioNTech begin the process of seeking full U.S. approval for their Covid vaccine - CNBC
cnbc.com - May 7 at 7:28 PM
BioNTech (NASDAQ:BNTX) Upgraded by Zacks Investment Research to "Strong-Buy"BioNTech (NASDAQ:BNTX) Upgraded by Zacks Investment Research to "Strong-Buy"
marketbeat.com - May 7 at 5:32 PM
Pfizer, BioNTech to provide COVID-19 vaccine to Olympic athletes - WTVB NewsPfizer, BioNTech to provide COVID-19 vaccine to Olympic athletes - WTVB News
wtvbam.com - May 7 at 2:28 PM
Coronavirus: Pfizer, BioNTech start process to seek full FDA approval for COVID-19 vaccine - FOX13 MemphisCoronavirus: Pfizer, BioNTech start process to seek full FDA approval for COVID-19 vaccine - FOX13 Memphis
fox13memphis.com - May 7 at 2:28 PM
BioNTech (NASDAQ:BNTX) Trading Up 8.7%BioNTech (NASDAQ:BNTX) Trading Up 8.7%
americanbankingnews.com - May 7 at 2:04 PM
Pfizer/BioNTech seek full FDA approval for its COVID-19 vaccine, plus more virus news - Quad City TimesPfizer/BioNTech seek full FDA approval for its COVID-19 vaccine, plus more virus news - Quad City Times
qctimes.com - May 7 at 9:27 AM
Coronavirus: Pfizer, BioNTech start process to seek full FDA approval for COVID-19 vaccine - WSOC CharlotteCoronavirus: Pfizer, BioNTech start process to seek full FDA approval for COVID-19 vaccine - WSOC Charlotte
wsoctv.com - May 7 at 9:27 AM
EU Set to Sign Off New Pfizer Vaccine Contract as Soon as Friday - BloombergEU Set to Sign Off New Pfizer Vaccine Contract as Soon as Friday - Bloomberg
bloomberg.com - May 7 at 9:27 AM
CSafe Global provides thermal protection for Covid-19 vaccine shipments from BioNTech facility | Supply Chain - Logistics Update AfricaCSafe Global provides thermal protection for Covid-19 vaccine shipments from BioNTech facility | Supply Chain - Logistics Update Africa
logupdateafrica.com - May 7 at 9:27 AM
Pfizer, BioNTech seek full FDA approval for COVID-19 vaccine - Fox BusinessPfizer, BioNTech seek full FDA approval for COVID-19 vaccine - Fox Business
foxbusiness.com - May 7 at 9:27 AM
Pfizer/BioNTech seek full FDA approval for their Covid-19 vaccine - CNN Pfizer/BioNTech seek full FDA approval for their Covid-19 vaccine - CNN
cnn.com - May 7 at 9:27 AM
Is a Surprise Coming for BioNTech (BNTX) This Earnings Season?Is a Surprise Coming for BioNTech (BNTX) This Earnings Season?
finance.yahoo.com - May 7 at 9:27 AM
Pfizer/BioNTech jab confirmed to protect 95 per cent in largest study yet - CTV NewsPfizer/BioNTech jab confirmed to protect 95 per cent in largest study yet - CTV News
ctvnews.ca - May 7 at 12:20 AM
Pfizer, BioNTech to provide Covid-19 vaccine to Olympic athletes - NBC NewsPfizer, BioNTech to provide Covid-19 vaccine to Olympic athletes - NBC News
nbcnews.com - May 7 at 12:20 AM
BioNTech Stock Pares Deep Losses After Angela Merkel Opposes Waiving Patents - Investors Business DailyBioNTech Stock Pares Deep Losses After Angela Merkel Opposes Waiving Patents - Investor's Business Daily
investors.com - May 6 at 7:20 PM
Pfizer and BioNTech to donate vaccines for Olympic athletes - KFGO NewsPfizer and BioNTech to donate vaccines for Olympic athletes - KFGO News
kfgo.com - May 6 at 7:20 PM
Pfizer-BioNTech COVID-19 Vaccine Significantly Prevents Infection, Severe Disease in Israel - Contagionlive.comPfizer-BioNTech COVID-19 Vaccine Significantly Prevents Infection, Severe Disease in Israel - Contagionlive.com
contagionlive.com - May 6 at 2:19 PM
Moderna, BioNTech Lead Losses on Vaccine IP Waivers - Yahoo FinanceModerna, BioNTech Lead Losses on Vaccine IP Waivers - Yahoo Finance
finance.yahoo.com - May 6 at 2:19 PM
Pfizer-BioNTech Can Supply 3 Billion Vaccine Doses This Year - BloombergPfizer-BioNTech Can Supply 3 Billion Vaccine Doses This Year - Bloomberg
bloomberg.com - May 6 at 2:19 PM
Pfizer, BioNTech to provide COVID-19 vaccine to Olympic athletes - WHBL NewsPfizer, BioNTech to provide COVID-19 vaccine to Olympic athletes - WHBL News
whbl.com - May 6 at 2:19 PM
BioNTech (NASDAQ:BNTX) Shares Gap Down to $170.77BioNTech (NASDAQ:BNTX) Shares Gap Down to $170.77
americanbankingnews.com - May 6 at 1:34 PM
Baillie Gifford & Co Buys Moderna Inc, The Trade Desk Inc, BioNTech SE, Sells Tesla Inc, ...Baillie Gifford & Co Buys Moderna Inc, The Trade Desk Inc, BioNTech SE, Sells Tesla Inc, ...
gurufocus.com - May 6 at 12:24 PM
BioNTech CEO says prospective 2021 vaccine output approaching 3 billion doses - KFGO NewsBioNTech CEO says prospective 2021 vaccine output approaching 3 billion doses - KFGO News
kfgo.com - May 6 at 1:54 AM
Pfizer-BioNTech vaccine approved for kids 12 to 15 years old in Canada – Aldergrove Star - Aldergrove StarPfizer-BioNTech vaccine approved for kids 12 to 15 years old in Canada – Aldergrove Star - Aldergrove Star
aldergrovestar.com - May 6 at 1:54 AM
BioNTech (NASDAQ:BNTX) PT Raised to $118.00 at SVB LeerinkBioNTech (NASDAQ:BNTX) PT Raised to $118.00 at SVB Leerink
marketbeat.com - April 19 at 8:34 AM
The Latest: Romanians protest restrictions as cases top 1MThe Latest: Romanians protest restrictions as cases top 1M
marketbeat.com - April 10 at 5:22 PM
The Latest: Lawmakers aim to limit state emergency powersThe Latest: Lawmakers aim to limit state emergency powers
marketbeat.com - April 10 at 4:05 PM
The Latest: Indian states warn of COVID-19 vaccine shortagesThe Latest: Indian states warn of COVID-19 vaccine shortages
marketbeat.com - April 10 at 6:14 AM
The Latest: Navajo Nation issues weekend stay-at-home orderThe Latest: Navajo Nation issues weekend stay-at-home order
marketbeat.com - April 9 at 10:43 PM
The Latest: Duke University to require vaccines by the fallThe Latest: Duke University to require vaccines by the fall
marketbeat.com - April 9 at 7:26 PM
How to Invest After a Turbulent 2020 Election (BNTX)How to Invest After a Turbulent 2020 Election (BNTX)
marketbeat.com - November 23 at 5:51 PM
COVID-19 Vaccine Results See AstraZeneca (LON:AZN) Slip a Bit (BNTX)COVID-19 Vaccine Results See AstraZeneca (LON:AZN) Slip a Bit (BNTX)
marketbeat.com - November 19 at 12:08 PM
DateCompanyBrokerageAction
5/4/2021AmgenRoyal Bank of CanadaLower Price Target
5/4/2021AmgenCredit Suisse GroupLower Price Target
5/4/2021AmgenSVB LeerinkLower Price Target
5/4/2021AmgenAtlantic SecuritiesReiterated Rating
5/3/2021AmgenOppenheimerLower Price Target
5/3/2021AmgenMorgan StanleyLower Price Target
4/29/2021AmgenRobert W. BairdReiterated Rating
4/29/2021AmgenEvercore ISIReiterated Rating
4/28/2021AmgenJPMorgan Chase & Co.Reiterated Rating
4/28/2021AmgenThe Goldman Sachs GroupReiterated Rating
4/28/2021AmgenBMO Capital MarketsLower Price Target
3/11/2021AmgenBarclaysLower Price Target
5/7/2021Gilead SciencesJefferies Financial GroupReiterated Rating
4/30/2021Gilead SciencesNeedham & Company LLCReiterated Rating
4/1/2021Gilead SciencesSanford C. BernsteinUpgrade
3/30/2021Gilead SciencesRedburn PartnersUpgrade
1/4/2021Gilead SciencesGuggenheimUpgrade
12/22/2020Gilead SciencesCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellLower Price Target
12/22/2020Gilead SciencesSmith Barney CitigroupLower Price Target
12/18/2020Gilead SciencesTruist FinancialLower Price Target
12/15/2020Gilead SciencesPiper SandlerLower Price Target
5/7/2021ModernaChardan CapitalBoost Price Target
3/4/2021ModernaBrookline Capital ManagementBoost Price Target
2/26/2021ModernaBank of AmericaReiterated Rating
4/23/2021BiogenHC WainwrightReiterated Rating
4/19/2021BiogenWedbushBoost Price Target
2/17/2021BiogenCantor FitzgeraldLower Price Target
2/5/2021BiogenDZ BankDowngrade
1/29/2021BiogenStifel NicolausUpgrade
12/1/2020BiogenWilliam BlairReiterated Rating
11/9/2020BiogenMizuhoLower Price Target
11/9/2020BiogenCowenDowngrade
4/6/2021BioNTechBerenberg BankSet Price Target
12/14/2020BioNTechCanaccord GenuityBoost Price Target
10/29/2020BioNTechCommerzbankInitiated Coverage
(Data available from 5/8/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.